Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 14/20 | 0.43 |
| ▸ | AKT1 | P31749 | 7/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732487 | 0.89 | RPS6KB1 (0.42) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL311144 | 0.86 | RPS6KB1 (0.47) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL4451812 | 0.78 | FFAR4 (0.41) | KCNH2KMOSCN9A | |
| SCHEMBL312365 | 0.78 | GPR119 (0.45) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL23705962 | 0.76 | SIGMAR1 (0.42) | — | |
| Hydrochloric Acid SCHEMBL310743 | 0.73 | MEN1 (0.57) | RPS6KB1AKT1 | |
| SCHEMBL3804657 | 0.73 | BTK (0.37) | KCNH2MCHR1KDM1A | |
| SCHEMBL4466566 | 0.73 | KMO (0.38) | KMO | |
| SCHEMBL311776 | 0.73 | TLR8 (0.45) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL4456610 | 0.72 | FFAR4 (0.40) | KCNH2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | RPS6KB1 6/4885AKT1 113/4885AKT2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.